A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.

Summary

This study was a randomized, double-blind, placebo-controlled phase I clinical trial of AP026 (TQA2226) for injection in adult healthy subjects, which planned to recruit 74 healthy subjects. The main purpose was to evaluate the safety and tolerance of AP026 (TQA2226) for injection after single and multiple doses in healthy subjects.

Timeline

Start

2023-05-24

Primary completion

2023-07-26

Completion

2026-03-16

Outcome

Outcome not reported

Stopped (Business): “Study terminated for strategic business reasons.”

Drugs

Indications